- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02757950
A Post-marketing, Observational, Retrospective Study to Assess the Safety of RefortrixTM (Tdap) When Administered During Pregnancy in a Maternal Immunization Program in Brazil.
A Post-marketing, Observational, Retrospective, Cohort Study to Assess the Safety of RefortrixTM (Tdap) When Administered During Pregnancy in a Maternal Immunization Program in Brazil.
Study Overview
Status
Conditions
Detailed Description
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
São Paulo
-
Santo Andre, São Paulo, Brazil, 09060-650
- GSK Investigational Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Subjects between 18 and 45 years of age at the time of pregnancy under consideration for the study, who deliver in the study centre.
- Residents of the study area
- Subjects who were compliant with the routine antenatal care including at least one ultrasound assessment report early in the pregnancy.
- Subjects with the complete and relevant medical records available.
Inclusion criteria for the Exposed cohort:
- Subjects who received one dose of Refortrix vaccine in the recommended time period between 27 and 36 completed weeks of pregnancy (or as late as 20 days before delivery due date) as part of the maternal immunization program in Brazil, and according to the program recommendations from May 2015 onwards.
- Subjects with appropriate vaccination records.
Inclusion criteria for the Unexposed cohort:
- Subjects who had delivered in the same hospital (study centre) before 01 September 2014 (September 2012-August 2014) and who did not receive Tdap vaccination during pregnancy to the best knowledge of the investigator.
Exclusion Criteria:
- Subjects who have been transferred to other specialised centres, where their medical records would be inaccessible for the study (private clinics, psychiatric or prison hospitals, other state hospitals, etc).
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Exposed cohort
Women, 18-45 years of age at the time of pregnancy, who delivered in the hospital (study centre) from May 2015 and who received one dose of Refortrix during 27 to 36 weeks of pregnancy (or as late as 20 days before delivery due date).
|
Subjects were included in the Exposed cohort if they received Refortrix as part of the maternal immunization program in Brazil.
|
Unexposed cohort
Women, 18-45 years of age at the time of pregnancy, who delivered in the hospital (study centre) before implementation of the maternal immunization program in Brazil in September 2014 and who did not receive Tdap vaccination during pregnancy.
|
Subjects were included in the Exposed cohort if they received Refortrix as part of the maternal immunization program in Brazil.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Subjects Reporting Gestational Diabetes
Time Frame: After week 27 of pregnancy
|
Gestational diabetes was defined as: Onset or first recognition of abnormal glucose tolerance during pregnancy (the diagnosis is based on administration of glucose challenge test at 24-28 weeks of gestation).
Includes Class A1: Euglycaemia achieved with diet and/or exercise and Class A2: Euglycaemia achieved with medication.
|
After week 27 of pregnancy
|
Number of Subjects Reporting Pregnancy-related Hypertension, Pre-eclampsia, Eclampsia, and HELLP Syndrome
Time Frame: After week 27 of pregnancy
|
Pregnancy-related hypertension is defined as: Blood pressure systolic higher than (>) 140 and/or diastolic > 90 millimetre of mercury (mmHg), documented in at least two separate measurements after 20 weeks of gestation, without proteinuria or other stigmata of pre-eclampsia, and returning to normal post-partum. Hypertension usually resolves by 12 weeks post-partum, included pre-eclampsia, eclampsia and haemolysis elevated liver enzymes low platelet (HELLP) Syndrome for this study. |
After week 27 of pregnancy
|
Number of Subjects Reporting Pregnancy Hemorrhage
Time Frame: After week 27 of pregnancy
|
Pregnancy vaginal hemorrhage is defined as: excessive blood loss after delivery i.e. estimated blood loss in excess of 500 milliliters (ml) after vaginal delivery and estimated blood loss in excess of 1000 ml after Caesarean delivery. The other symptoms are higher than or equal to (≥) 10 percent (%) drop in hematocrit, need for blood transfusion, symptomatic hypotension, dizziness, pallor and oliguria. Vaginal or intrauterine hemorrhage that encompasses antepartum (i.e. bleeding from the genital tract after 24 weeks of gestation), intrapartum, and postpartum bleeding (i.e. within 24 hours post-delivery). A major obstetric hemorrhage is defined as blood loss from uterus or genital tract >1500 ml or a decrease. |
After week 27 of pregnancy
|
Number of Subjects With Pre-specified Neonate-related Outcomes Resulting in Preterm Birth
Time Frame: From week 27 up to week 37 of pregnancy
|
Preterm birth is defined as: Birth before 37 weeks of gestation.
|
From week 27 up to week 37 of pregnancy
|
Number of Subjects With Pre-specified Neonate-related Outcomes, Resulting in Neonates Small for Their Gestational Age
Time Frame: After week 27 of pregnancy
|
Small for gestational age is defined as: Birth weight less than (<) 10% for infants of same gestational age and gender in same population.
|
After week 27 of pregnancy
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Subjects Reporting Pregnancy-related Adverse Events (AEs) of Interest/Neonate-related Events up to Delivery
Time Frame: After week 27 of pregnancy
|
Pregnancy-related AEs of interest and neonate-related events are defined as: premature rupture of membranes, preterm premature rupture of membranes, premature uterine contraction, neonatal death, maternal death, still birth, neonatal hypoxic ischaemic encephalopathy.
|
After week 27 of pregnancy
|
Number of Subjects Reporting Cases of Congenital Anomalies in the Neonates
Time Frame: From week 27 of pregnancy up to birth
|
Congenital anomalies include morphological, functional, chromosomal or genetic anomalies, regardless of whether detected at birth or not, the foetus is delivered dead or alive, or defects are identified by prenatal ultrasound, amniocentesis or examination of the products of conception.
|
From week 27 of pregnancy up to birth
|
Number of Subjects With Pregnancy-related AEs and Birth Outcomes Per Calendar Year
Time Frame: After week 27 of pregnancy
|
Pregnancy related AEs include: gestational diabetes, pregnancy-related hypertension, pre-eclampsia, eclampsia, HELLP Syndrome and pregnancy hemorrhage.
Birth outcomes include: preterm birth and small for gestational age.
|
After week 27 of pregnancy
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 203153
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diphtheria
-
Hillel Yaffe Medical CenterRecruitingDiphtheria-Tetanus-acellular Pertussis VaccinesIsrael
-
GlaxoSmithKlineCompletedDiphtheria-Tetanus-acellular Pertussis VaccinesFinland, Australia, Spain, Italy, Canada, Czechia
-
ABO Holdings, Inc.Active, not recruitingTetanus, Diphtheria and Acellular Pertussis VaccinationUnited States
-
National Institute of Allergy and Infectious Diseases...CompletedPertussis | Tetanus | Diphtheria | Diphtheria Immunisation | Tetanus Immunisation | Clostridium Difficile ImmunisationMali
-
Women and Infants Hospital of Rhode IslandNot yet recruitingVaccine Exposure During Pregnancy | Tdap - Tetanus, Diphtheria and Acellular Pertussis Vaccination | Non-birthing Partner Vaccination in Pregnancy
-
GlaxoSmithKlineTerminatedDiphtheria-Tetanus-Acellular PertussisColombia
-
Sanofi Pasteur, a Sanofi CompanyCompletedDiphtheria, Tetanus and PertussisSpain
-
MassBiologicsCompleted
-
Institute of Arthritis ResearchLouisiana State University Health Sciences Center in New Orleans; Brigham Young...Not yet recruitingPre-Eclampsia | Diphtheria, Tetanus and Pertussis Vaccine ReactionUnited States
-
GlaxoSmithKlineCompletedDiphtheria-Tetanus-acellular Pertussis VaccinesRussian Federation
Clinical Trials on Combined diphtheria, tetanus and tricomponent acellular pertussis vaccine [Refortrix (Tdap)]
-
Sanofi Pasteur, a Sanofi CompanyCompletedPertussis | Tetanus | DiphtheriaUnited States, Canada
-
Mindful Diagnostics and Therapeutics, LLCInfectious Disease Society of AmericaNot yet recruiting
-
CanSino Biologics Inc.Henan Center for Disease Control and PreventionCompletedPertussis | Tetanus | DiphtheriaChina
-
GlaxoSmithKlineCompletedTetanus | Diphtheria | Acellular PertussisUnited States
-
Beijing Zhifei Lvzhu Biopharmaceutical Co., LtdRecruitingHealthy VolunteersChina
-
Sanofi Pasteur, a Sanofi CompanyTerminatedDengue Fever | Dengue Hemorrhagic FeverPhilippines
-
China National Biotec Group Company LimitedBeijing Institute of Biological Products Co Ltd.Active, not recruitingWhooping Cough | Tetanus | DiphtheriaChina
-
GlaxoSmithKlineCompletedPertussis | Tetanus | Diphtheria
-
Sanofi Pasteur, a Sanofi CompanyCompletedPertussis | Tetanus | DiphtheriaChina
-
Sanofi Pasteur, a Sanofi CompanyCompletedPertussis | Tetanus | DiphtheriaUnited States, Canada